# Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

> **NCT06577337** · PHASE1 · RECRUITING · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 49 (estimated)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** M5542
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06577337
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2026-11-18
- **Final completion:** 2027-03-09
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577337, "Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06577337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*